[In vitro antibacterial activity of sulperazone on multi-resistant strains of bacteria from burn wounds].
Sulperazone (SLP), a combination of sulbactam (beta-lactamase inhibitor) with cefoperazone (CFP), was studied in vitro for its sensitivity to multi-resistant strains of bacteria isolated from burn wounds. The results showed that the sensitive rate of gram-negative bacteria to SLP was 77.3% (n = 163), higher than that of CFP (45.0%, n = 169) (P < 0.01). The rate of pseudomonas aeruginosa which was common among the gram-negative bacteria was 88.9% (n = 45), much higher than that of CFP (71.7%, n = 46) (P < 0.05). The rate of bacterium anitratum was 100%, and it was resistant to CFP (P < 0.01). The sensitive rate of gram-positive bacteria to SLP was 37.5% (n = 128) but to CFP was 24.6% (n = 126) (P < 0.05). The rate of staphylococcus aureus which was common in gram-positive bacteria was 42.6% (n = 61), much higher than that of CFP (21.3%, n = 61) (P < 0.05). It is indicated that sulbactam inhibits most beta-lactamases produced by common bacterial pathogens and makes antibiotics restore the sensitivity to resistant strains. Sulperazone is promising in the treatment of burn infection.
Xu
W
W
Ruijin Hospital, Shanghai Second Medical University.
Chen
X
X
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002056:Burns / Q000382:microbiology; D002438:Cefoperazone / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004338:Drug Combinations; D018432:Drug Resistance, Multiple; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D002438:Cefoperazone; D013407:Sulbactam